
technologyJan 26, 20266:19pending
AI in Drug Trials, Pfizer's Innovations, and NVIDIA's CoreWeave Partnership
About this episode
In this episode, Bob introduces the role of AI in drug development, particularly its impact on streamlining clinical trials. The discussion then shifts to Pfizer's recent innovations in AI, which have reportedly reduced the time to market for new drugs. Bob highlights Recursive's advancements in self-improving AI systems and their recent funding achievements. Attention is given to NVIDIA's collaboration and investment in CoreWeave's AI factories, which aim to bolster AI infrastructure. The episode concludes with closing remarks and an outlook on future developments in AI, emphasizing the importance of these advancements in shaping the industry.
Get every episode summarized
Each time The AI News Daily Brief publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The AI News Daily Brief

China's AI Innovations, Physical AI Advances, and Legal Sector Challenges
The AI News Daily Brief
Apr 13, 202615:09failed

AI in Cybersecurity, Healthcare Advances, and Surveillance Debates
The AI News Daily Brief
Apr 6, 202610:25failed

AI in Google Maps, Pharma Partnerships, and Ethical Challenges in Drone Warfare
The AI News Daily Brief
Mar 30, 20266:55failed

AI's Economic Impact, Interloom's Funding, and Europe's Energy-AI Nexus
The AI News Daily Brief
Mar 23, 202610:56failed